HLS Therapeutics (TSE:HLS) Hits New 52-Week Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s share price hit a new 52-week low during mid-day trading on Thursday . The company traded as low as C$4.11 and last traded at C$4.00, with a volume of 4274 shares traded. The stock had previously closed at C$4.12.

HLS Therapeutics Price Performance

The firm has a market cap of C$126.04 million, a P/E ratio of -12.59 and a beta of -0.18. The business has a 50-day simple moving average of C$4.27 and a 200 day simple moving average of C$4.44. The company has a debt-to-equity ratio of 75.00, a quick ratio of 1.01 and a current ratio of 1.00.

HLS Therapeutics (TSE:HLS) last issued its quarterly earnings data on Friday, May 15th. The company reported C($0.10) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative net margin of 18.42% and a negative return on equity of 16.54%. The company had revenue of C$17.88 million for the quarter. On average, analysts anticipate that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.